Access the full text.
Sign up today, get DeepDyve free for 14 days.
M Naderi, A Saeedi, A Moradi, M Kleshadi, MR Zolfaghari, A Gorji, A Ghaemi (2013)
Interleukin-12 as a genetic adjuvant enhances hepatitis C virus NS3 DNA vaccine immunogenicityVirol Sin, 28
X Ma, X Forns, R Gutierrez, IK Mushahwar, T Wu, PJ Payette, J Bukh, RH Purcell, HL Davis (2002)
DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in miceVaccine, 20
IA Doytchinova, P Guan, DR Flower (2006)
EpiJen: a server for multistep T cell epitope predictionBMC Bioinform, 7
C Moser, M Müller, MD Kaeser, U Weydemann, M Amacker (2013)
Influenza virosomes as vaccine adjuvant and carrier systemExpert Rev Vaccines, 12
H Wedemeyer, S Gagneten, A Davis, R Bartenschlager, S Feinstone, B Rehermann (2001)
Oral immunization with HCV NS3 transformed Salmonella: induction of HCV specific CTL in a transgenic mouse modelGastroenterology, 12
J Reyes–del Valle, C de la Fuente, MA Turner, C Springfeld, S Apte-Sengupta, ME Frenzke, A Forest, J Whidby, J Marcotrigiano, CM Rice, R Cattaneo (2012)
Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein boosterJ Virol, 86
JM Wu, H Chen, ZY Sheng, J Wang, DY Fan, N Gao, J An (2012)
The adjuvant effect of granulocyte macrophage colony stimulating factor (GM-CSF) in dengue virus and hepatitis C virus DNA vaccinesBing Du Xue Bao, 28
S Mishima, K Saito, H Maruyama, M Inoue, T Yamashita, T Ishida, Y Gu (2004)
Antioxidant and immuno-enhancing effects of Echinacea purpureaBiol Pharm Bull, 27
S Dueñas-Carrera (2004)
DNA vaccination against hepatitis CCurr Opin Mol Ther, 6
E De Gregorio, E Caproni, JB Ulmer (2013)
Vaccine adjuvants: mode of actionFront Immunol, 4
O Weiland, G Ahlén, H Diepolder, MC Jung, S Levander, M Fons, I Mathiesen, NY Sardesai, A Vahlne, L Frelin, M Sällberg (2013)
Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis CMol Ther, 21
B Wen, Y Deng, H Chen, J Guan, X Chuai, L Ruan, W Kong, W Tan (2013)
The novel replication-defective vaccinia virus (Tiantan Strain)—based hepatitis C virus vaccine induces robust immunity in macaquesMol Ther, 21
Y Lin, T Kwon, J Polo, YF Zhu, S Coates, K Crawford, C Dong, M Wininger, J Hall, M Selby, D Coit, A Medina-Selby, C McCoin, P Ng, D Drane, D Chien, J Han, M Vajdy, M Houghton (2008)
Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5J Virol, 82
SF Abdelwahab, M Hashem, I Galal, M Sobhy, TS Abdel-Ghaffar, G Galal, N Mikhail, SS El-Kamary, I Waked, GT Strickland (2013)
Incidence of hepatitis C virus infection among Egyptian healthcare workers at high risk of infectionJ Clin Virol, 57
Y EL-Manzalawy, D Dobbs, V Honavar (2008)
Prediction of linear B-cell epitopes using string kernelsJ Mol Recognit, 21
H Pantua, J Diao, M Ultsch, M Hazen, M Mathieu, K McCutcheon, K Takeda, S Date, TK Cheung, Q Phung, P Hass, D Arnott, JA Hongo, DJ Matthews, A Brown, AH Patel, RF Kelley, C Eigenbrot, SB Kapadia (2013)
Glycan shifting on hepatitis c virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodiesJ Mol Biol, 425
J Cao, Z Chen, Y Ren, Y Luo, M Cao, W Lu, P Zhao, Z Qi (2011)
Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in miceVaccine, 29
ME Assayed (2010)
Radioprotective effects of black seed (Nigella sativa) oil against hemopoietic damage and immunosuppression in gamma-irradiated ratsImmunopharmacol Immunotoxicol, 32
M Houghton, S Abrignani (2005)
Prospects for a vaccine against the hepatitis C virusNature, 436
MR Wilkins, E Gasteiger, A Bairoch, JC Sanchez, KL Williams, RD Appel, DF Hochstrasser (1999)
Protein identification and analysis tools in the ExPASy serverMethods Mol Biol, 112
S Möller, MDR Croning, R Apweiler (2001)
Evaluation of methods for the prediction of membrane spanning regionsBioinformatics, 17
E Scarselli, H Ansuini, R Cerino, RM Roccasecca, S Acali, G Filocamo, C Traboni, A Nicosia, R Cortese, A Vitelli (2002)
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virusEMBO J, 21
C Bode, G Zhao, F Steinhagen, T Kinjo, DM Klinman (2011)
CpG DNA as a vaccine adjuvantExpert Rev Vaccines, 10
V Randianarison, M Perricaudet (1995)
Recombinant adenoviruses as vaccinesBiologicals, 23
D Lavillette, AW Tarr, C Voisset, P Donot, B Bartosch, C Bain, AH Patel, J Dubuisson, JK Ball, FL Cosset (2005)
Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virusHepatology, 41
G Vriend (1990)
WHAT IF: a molecular modeling and drug design programJ Mol Graph, 8
E Engvall, P Perlmann (1971)
Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin GImmunochem, 8
Q Qiu, RY Wang, X Jiao, B Jin, F Sugauchi, T Grandinetti, HJ Alter, JW Shih (2008)
Induction of multispecific Th-1 type immune response against HCV in mice by protein immunization using CpG and Montanide ISA 720 as adjuvantsVaccine, 26
J Xue, H Zhu, Z Chen (2014)
Therapeutic vaccines against hepatitis C virusInfect Genet Evolut, 22
MJ Evans, T von Hahn, DM Tscherne, AJ Syder, M Panis, B Wolk, T Hatziioannou, JA McKeating, PD Bieniasz, CM Rice (2007)
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entryNature, 446
MM Bahgat, K Chlichlia, V Schirrmacher, A Ruppel (2002)
Antibodies induced in mice by a DNA-construct coding for the elastase of Schistosoma mansoni recognize the enzyme in secretions and preacetabular glands of cercariaeParasitology, 124
RA Laskowski, MW MacArthur, DS Moss, JM Thornton (1993)
PROCHECK - a program to check the stereochemical quality of protein structuresJ App Cryst, 26
I Zubkova, H Duan, F Wells, H Mostowski, E Chang, K Pirollo, K Krawczynski, R Lanford, M Major (2014)
Hepatitis C virus clearance correlates with HLA-DR expression on proliferating CD8+ T cells in immune primed chimpanzeesHepatology, 59
IA Doytchinova, DR Flower (2007)
VaxiJen: a server for prediction of protective antigens, tumor antigens and subunit vaccinesBMC Bioinform, 8
RJ Lock, DJ Unsworth (2000)
Measurement of immune complexes is not useful in routine clinical practiceAnn Clin Biochem, 37
P Pileri, Y Uematsu, S Campagnoli, G Galli, F Falugi, R Petracca, AJ Weiner, M Houghton, D Rosa, G Grandi, S Abrignani (1998)
Binding of hepatitis C virus to CD81Science, 282
PV Licciardi, JR Underwood (2011)
Plant-derived medicines: a novel class of immunological adjuvantsInt Immunopharmacol, 11
B Rost (1996)
PHD: predicting one-dimensional protein structure by profile-based neural networksMethods Enzymol, 266
J Guan, B Wen, Y Deng, K Zhang, H Chen, X Wu, L Ruan, W Tan (2011)
Effect of route of delivery on heterologous protection against HCV induced by an adenovirus vector carrying HCV structural genesVirol J, 8
J Liu, L Zhu, X Zhang, M Lu, Y Kong, Y Wang, G Li (2001)
Expression, purification, immunological characterization and application of Escherichia coli-derived hepatitis C virus E2 proteinsBiotechnol Appl Biochem, 34
C Firbas, B Jilma, E Tauber, V Buerger, S Jelovcan, K Lingnau, M Buschle, J Frisch, CS Klade (2006)
Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjectsVaccine, 24
H Towbin, T Staehelin, L Godon (1979)
Electrophoresis transfer of protein from polyacrylamide gels to nitrocellulose sheets: procedure and some applicationsProc Natl Acad Sci USA, 76
A Ploss, MJ Evans, VA Gaysinskaya, M Panis, H You, Y de Jong, CM Rice (2009)
Human occludin is a hepatitis C virus entry factor required for infection of mouse cellsNature, 457
N Kushnir, SJ Streatfield, V Yusibov (2012)
Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical developmentVaccine, 31
G Martinez-Donato, Y Amador-Cañizares, L Alvarez-Lajonchere, I Guerra, A Pérez, J Dubuisson, C Wychowsk, A Musacchio, D Aguilar, S Dueñas-Carrera (2014)
Neutralizing antibodies and broad functional T cell immune response following immunization with hepatitis C virus proteins-based vaccine formulationVaccine, 32
M Beld, M Penning, M McMorrow, J Gorgels, A Van den Hoek, J Goudsmit (1998)
Different hepatitis C virus (HCV) RNA load profiles following seroconversion among injecting drug users without correlation with HCV genotype and serum alanine aminotransferase levelsJ Clin Microbiol, 36
MA Naarding, E Falkowska, H Xiao, T Dragic (2011)
Hepatitis C virus soluble E2 in combination with QuilA and CpG ODN induces neutralizing antibodies in miceVaccine, 29
DA Garber, LA O’Mara, J Zhao, S Gangadhara, I An, MB Feinberg (2009)
Expanding the repertoire of modified vaccinia Ankara-based vaccine vectors via genetic complementation strategiesPLoS One, 4
M Wiederstein, MJ Sippl (2007)
ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteinsNucleic Acids Res, 35
AS Maghraby, MM Bahgat (2004)
Immunostimulatory effect of coumarin derivatives before and after infection of mice with the parasite Schistosoma mansoniArzneimittelforschung, 54
J Liu, Y Kong, L Zhu, Y Wang, G Li (2002)
High-level expression of the C-terminal hydrophobic region of HCV E2 protein ectodomain in E. coliVirus Genes, 25
MK El-Awady, AA Tabll, YS El-Abd, H Yousif, M Hegab, M Reda, R El Shenawy, RI Moustafa, N Degheidy, NG El-Din (2009)
Conserved peptides within the E2 region of hepatitis C virus induce humoral and cellular responses in goatsVirol J, 6
LJ McGuffin, K Bryson, DT Jones (2000)
The PSIPRED protein structure prediction serverBioinformatics, 16
ME Major (2009)
Prophylactic and therapeutic vaccination against hepatitis C virus (HCV): developments and future perspectivesViruses, 1
JV Kringelum, C Lundegaard, O Lund, M Nielsen (2012)
Reliable B cell epitope predictions: impacts of method development and improved benchmarkingPLoS Comput Biol, 8
C Verheust, M Goossens, K Pauwels, D Breyer (2012)
Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccinationVaccine, 30
DT O’Hagan, M Singh, C Dong, M Ugozzoli, K Berger, E Glazer, M Selby, M Wininger, P Ng, K Crawford, X Paliard, S Coates, M Houghton (2004)
Cationic microparticles are a potent delivery system for a HCV DNA vaccineVaccine, 23
R Vita, L Zarebski, JA Greenbaum, H Emami, I Hoof, N Salimi, R Damle, A Sette, B Peters (2010)
The immune epitope database 2.0Nucleic Acids Res, 38
N Guex, MC Peitsch (1997)
SWISS-MODEL and the Swiss-Pdb Viewer: an environment for comparative protein modelingElectrophoresis, 18
C Hartoonian, M Ebtekar, H Soleimanjahi, A Karami, M Mahdavi, N Rastgoo, K Azadmanesh (2009)
Effect of immunological adjuvants: GM-CSF (granulocyte-monocyte colony stimulating factor) and IL-23 (interleukin-23) on immune responses generated against hepatitis C virus core DNA vaccineCytokine, 46
MK El-Awady, MA El-Demellawy, SB Khalil, D Galal, SA Goueli (2002)
Synthetic peptide-based immunoassay as a supplemental test for HCV infectionClin Chim Acta, 325
The present work aimed at 1) characterization of the E1 and E2 proteins (HCV-E) from an Egyptian hepatitis C virus genotype 4a (HCV-4a) isolateat the molecular and immunological level, 2) in silico identification of the B- and T-cell epitopes responsible for the immunogenicity of HCV-E, and 3) evaluation of the diagnostic potential of both the recombinant HCV-E and antibodies raised using mammalian expression constructs encoding the protein. The region encoding the E1 and E2 proteins was amplified by RT-PCR from RNA isolated from blood of a human infected with HCV-4 and cloned into the pSC-TA plasmid, and the sequence was verified and used to construct a neighbor-joining phylogenetic tree. The translated nucleotide sequence was used to predict the HCV-E secondary structure using the PREDICT-PROTEIN server and PSI-PRED. A 3D model of HCV-E was generated using the online tool 3Dpro. B- and T-cell epitopes were predicted using the online tools BCPred and Epijen v1.0, respectively. The HCV-E-encoding sequence was later subcloned into the mammalian expression plasmid pQE, and the constructs that were generated were used to immunize mice in the absence and presence of adjuvants of plant origin. The maximum sequence identity obtained by nucleotide and protein BLAST analysis with previously published HCV-E sequences was 85 and 77 %, respectively. The B-cell epitope CFTPSPVVV at position 203 and the T-cell epitope ALSTGLIHL at position 380 were found to be highly conserved among all HCV genotypes. Both ELISA and Western blotting experiments on crude and purified recombinant HCV envelope proteins using mouse antisera raised using the HCV-E mammalian expression construct confirmed the specific antigenicity of the expressed protein. The antibodies raised in mice using the HCV-E-encoding construct could efficiently capture circulating antigens in patients’ sera with good sensitivity that correlated with liver enzyme levels (r = 0.4052, P < 0.0001 for ALT; r = −0.5439, P = 0.0019 for AST). Moreover, combining the HCV-E-encoding construct with extracts prepared from Echinacea purpurea and Nigella sativa prior to immunizing mice significantly (P < 0.05) increased both the humoral (14.9- to 20-fold increase in antibodies) and the cellular (CD4+ and cytotoxic CD8+- T lymphocytes) responses compared to mice that received the DNA construct alone or PBS-treated mice. Both recombinant HCV-E protein preparations and antibodies raised using the HCV-E-encoding mammalian expression construct represent useful diagnostic tools that can report on active HCV infection. Also, the immunostimulatory effects induced by the two plant extracts used at the cellular and humoral level highlight the potential of natural products for inducing protection against HCV infection. The neutralizing capacity of the induced antibodies is a subject of future investigations. Furthermore, the predicted B- and T-cell epitopes may be useful for tailoring future diagnostics and candidate vaccines against various HCV genotypes.
Archives of Virology – Springer Journals
Published: Apr 1, 2015
Keywords: Echinacea Purpurea; Mouse Antiserum; Translate Nucleotide Sequence; Antigenic Score; Mammalian Expression Construct
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.